RVU120 (selinexor analog)
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Phase 1/2Active
Key Facts
Indication
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Phase
Phase 1/2
Status
Active
Company
About Ryvu Therapeutics
Ryvu Therapeutics is a Polish public company advancing a portfolio of targeted oncology therapies, with its lead programs in clinical trials. The company leverages a proprietary drug discovery platform to identify and develop small molecule inhibitors against novel targets like STING and HPK1. Its strategy combines internal R&D with strategic partnerships to advance its pipeline and create value. As a clinical-stage firm, it is pre-revenue and funded through equity offerings and collaborations.
View full company profileTherapeutic Areas
Other Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) Drugs
| Drug | Company | Phase |
|---|---|---|
| TSC-101 | TScan Therapeutics | Phase 1 |